Juno Therapeutics (JUNO) Posts Q4 Loss of $1.61/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Juno Therapeutics Reports Fourth Quarter and 2014 Financial Results
March 18, 2015 4:02 PM EDTConference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time
Positive momentum and progress on clinical trials continues Strong year-end cash position of $474.1 million 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and ongoing litigationSEATTLE, March 18, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial... More
Juno Therapeutics Reports Fourth Quarter and 2014 Financial Results
March 18, 2015 4:02 PM EDTConference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time
Positive momentum and progress on clinical trials continues Strong year-end cash position of $474.1 million 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and ongoing litigationSEATTLE, March 18, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial... More
